Skip to content

Role of Endocrine Disruptors in Thyroid Cancer

Cross-sectional Case-control Study on the Role of Endocrine Disruptors in Thyroid Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05747365
Acronym
THY-ED
Enrollment
222
Registered
2023-02-28
Start date
2022-07-12
Completion date
2025-07-31
Last updated
2024-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocrine Disruptor Chemicals, Thyroid Cancer

Brief summary

the relationship between human exposure to EDCS and TC is poorly investigated and still unclear. The aim of this study is to evaluate the possible role of old and new generation endocrine disruptors in thyroid cancer. The primary aim is to evaluate the difference in the average levels of the main endocrine disruptors (PFAS, including: PFOA, PFOS, PFDA, PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates, parabens, PCBs, flame retardants) between patients with and without a diagnosis of thyroid cancer through highly sensitive, selective and precise mass spectrometry methods, such as liquid chromatography combined with tandem mass spectrometry (LC-MS / MS). The secondary aim is to evaluate the relationship between the concentrations of endocrine disruptors and some anamnestic variables studied (for example the type of diet, the use of personal care products).

Interventions

DIAGNOSTIC_TESTBlood and urine diagnostic evaluation

Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations

Sponsors

Istituto Auxologico Italiano
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with a diagnosis of thyroid cancer in the last 5 years (arm A) * patients without a diagnosis of thyroid cancer will match patients included in arm A

Exclusion criteria

* subjects under 18 years old * patients unable to sign the informed consent or questionnaires

Design outcomes

Primary

MeasureTime frameDescription
Difference in the average levels of the main endocrine disruptorsAt recruitmentThe main endocrine disruptors evaluated will be PFAS, including: PFOA, PFOS, PFDA, PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates, parabens, PCBs, flame retardants
Relationship between the concentrations of endocrine disruptors and anamnestic variablesAt recruitmentRelationship between the concentrations of endocrine disruptors and some anamnestic variables studied (for example the type of diet, the use of personal care products).

Countries

Italy

Contacts

Primary ContactLaura Fugazzola, MD
l.fugazzola@auxologico.it+390261911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026